Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paenibacillus larvae bacterin
- Development stage
- Unknown
- Lead developer
- Dalan Animal Health
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Paenibacillus larvae bacterin is a conditionally licensed vaccine developed to protect honey bee colonies (Apis mellifera) against American foulbrood (AFB), a highly destructive and notifiable bacterial disease caused by the spore-forming gram-positive microorganism Paenibacillus larvae. The vaccine is composed of inactivated whole-cell P. larvae bacteria (bacterin) and works by stimulating the immune response in queen bees, which then pass immunity to their offspring, thereby reducing colony losses due to AFB. This product represents the first approved vaccine for honey bees and marks a significant advance in apiculture health management[2][6]. The primary indication is prevention of American foulbrood in managed honey bee populations.
- Brand names
- Paenibacillus Larvae Bacterin
- Other names
- paenibacillus larvae bacterin
02
Targets
Paenibacillus larvae
Beyond the preview
Go deeper on Paenibacillus larvae bacterin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Paenibacillus larvae bacterin.